Log in

Relevant bibliographies by topics / Ohtuvayre

Contents

Journal articles

Academic literature on the topic 'Ohtuvayre'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Ohtuvayre.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Ohtuvayre"

1

Arshpreet, Kaur. "Evaluating the Effectiveness of Ohtuvayre Regimen Over Albuterol in COPD Management." International Journal of Clinical Science and Medical Research 05, no. 03 (2025): 54–56. https://doi.org/10.5281/zenodo.14959107.

Full text

Abstract:

ABSTRACT : One of the main causes of morbidity and poor health worldwide is Chronic Obstructive Pulmonary Disease (COPD) (World Health Organisation, 2024.). Over the last two decades, inhalation treatments had not advanced very much. Still, the U.S. Food and Drug Administration (FDA)'s recent approval of Ohtuvayre (ensifentrine) has brought a first-inclass inhalation medication combining bronchodilator and anti-inflammatory properties via dual inhibition of phosphodiesterase enzymes PDE3 and PDE4. Many trials have confirmed the usage of the new medicine by showing considerable increases in for

APA, Harvard, Vancouver, ISO, and other styles

2

Marino, Adriane B., Jenna D. Theroux, Evan S. Drake, James Layton Anderson, and Destiny S. Self. "The Drug Update." Nurse Practitioner 50, no. 2 (2025): 27–40. https://doi.org/10.1097/01.npr.0000000000000271.

Full text

Abstract:

ABSTRACT In the first half of 2024, the US FDA approved several new drugs that have relevance for those practicing in primary care. This article, the winter 2025 edition of the journal's biannual Drug Update, highlights the following new medications: sotatercept-csrk (Winrevair), aprocitentan (Tryvio), resmetirom (Rezdiffra), berdazimer (Zelsuvmi), ceftobiprole medocaril sodium (Zevtera), sofpironium (Sofdra), and ensifentrine (Ohtuvayre).

APA, Harvard, Vancouver, ISO, and other styles

3

Cuéllar Rodríguez, Santiago. "Novel drugs recently authorized by ema and fda (Q2, 2024)." Anales de la Real Academia Nacional de Farmacia, no. 90(02) (July 1, 2024): 279–92. http://dx.doi.org/10.53519/analesranf.2024.02.08.

Full text

Abstract:

Newly approved drugs: (A) TRACTO ALIMENTARIO Y METABOLISMO: Diabetes mellitus: Insulina Icodec (Awiqli®; EMA). Colangitis biliar primaria: Elafibranor (Iqirvo®; FDA).(B) SANGRE Y SISTEMA HEMATOPOYÉTICO: Hemofilia B: Fidanacogene Elaparvovec (Beqvez®; FDA). (C) SISTEMA CARDIOVASCULAR: (D) DERMATOLOGÍA: Hiperhidrosis axilar primaria: Sofpironio (Sofdra®; FDA). (G) SISTEMA GENITOURINARIO Y HORMONAS SEXUALES: Vejiga hiperactiva: Vibegron (Obgemsa®; EMA). (J) ANTIINFECCIOSOS SISTÉMICOS: Infección intraabdominal: Aztreonam / Avibactam (Emblaveo®; EMA). Neumonía neumocócica: Vacuna neumococo polisacá

APA, Harvard, Vancouver, ISO, and other styles

4

"Ensifentrine (Ohtuvayre) for COPD." Medical Letter on Drugs and Therapeutics 66, no. 1709 (2024): 131–33. http://dx.doi.org/10.58347/tml.2024.1709b.

Full text

Abstract:

The FDA has approved ensifentrine (Ohtuvayre – Verona), an inhaled phosphodiesterase (PDE) 3 and 4 inhibitor, for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It is the first dual inhibitor of PDE3 and PDE4 to be approved by the FDA, and the first inhaled drug with a new mechanism of action to be approved for treatment of COPD in more than 20 years.

APA, Harvard, Vancouver, ISO, and other styles

5

Hubert, Sandra, Ayrin Kök-Carrière, and Frédéric De Ceuninck. "Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease." Trends in Pharmacological Sciences, September 2024. http://dx.doi.org/10.1016/j.tips.2024.08.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Spina, Domenico, Lui Franciosi, Radhakrishnan Venkatasamy, David A. Saint, Margot MacDonald-Berko, and Tara Rheault. "Anti-Inflammatory Activity of Ensifentrine, a Novel, Selective Dual Inhibitor of Phosphodiesterase (PDE)3 and PDE4." Respiration, April 17, 2025, 1–18. https://doi.org/10.1159/000545645.

Full text

Abstract:

Ensifentrine is a novel, low molecular weight molecule that is a selective, dual inhibitor of phosphodiesterase (PDE)3 and PDE4. Inhibition of PDE3 has been shown to relax airway smooth muscle and inhibition of PDE4 to inhibit inflammatory responses and to stimulate the cystic fibrosis transmembrane conductance regulator in human airway epithelial cells through accumulation of intracellular cyclic adenosine monophosphate. Additionally, the dual inhibition of PDE3 and PDE4 demonstrates enhanced or synergistic effects compared with inhibition of either PDE3 or PDE4 alone on contraction of airway

APA, Harvard, Vancouver, ISO, and other styles

7

Hitt, Emily M., and Alexa J. Powell. "Ensifentrine: A Novel Option for Maintenance of Chronic Obstructive Pulmonary Disease." Journal of Pharmacy Technology, June 24, 2025. https://doi.org/10.1177/87551225251350899.

Full text

Abstract:

Objective: The goals of this article are reviewing the clinical aspects of ensifentrine, results from the clinical trials that led to its approval and examining its potential impact on patient care to aid therapeutic decision-making. Data Sources: A literature search of studies took place between October 2024 and December 2024 on PubMed using the terms ensifentrine, roflumilast, Ohtuvayre™ and ensifentrine chronic obstructive pulmonary disease (COPD). Study selection/data extraction: Phase II and III randomized controlled trials were eligible for inclusion. Pertinent clinical trials included t

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!